Lilly Sees More Dealmaking as GLP-1 Wins Expand Market
Eli Lilly’s GLP-1 drugs have changed the game in obesity and diabetes. This article explains why Lilly Sees More Deal...
Find beginner-friendly options with understandable use cases and liquidity, plus a simple framework to compare potential investments.
27,615 articlesEli Lilly’s GLP-1 drugs have changed the game in obesity and diabetes. This article explains why Lilly Sees More Deal...
Rivian shocks investors by cutting jobs shortly after starting to deliver the R2. This move raises questions about ho...
Ciena’s shares jumped sharply in the first half of 2026. This article dives into the AI-driven demand for optical net...
Palo Alto Networks’ stock fell after the latest earnings, as traders weighed a murky near-term outlook against the co...
Apple’s latest strategy signals a shift from pure premium to share growth. This article explores how pricing, service...
Peloton reports fresh restructuring amid a stubborn demand slump and rising costs. The destruction peloton continues ...
Investors are watching Health Catalyst as healthcare data analytics gain budget priority. This guide breaks down what...
As a new Fed chair, chair kevin warsh will confront two high-stakes tests in just 100 days. One test centers on polit...
SSR Mining stock surged again as gold prices nudged higher and a strategic asset sale hinted at improved cash flow. T...
As AI spending hits record levels, Chamath Palihapitiya argues the real test is whether buyers of AI can deliver dura...
CoStar Group blends a high performing CRE data backbone with a slower moving homes marketplace. This piece breaks dow...
When the broader market fell, one name stood out. This article explains why plug power stock defied the downturn, fea...